NCT06861855

Brief Summary

  1. 1.To evaluate immunohistochemical expression of METTL14 in type1 endometrial carcinoma.
  2. 2.To evaluate the correlation between METTL14 expression and clinicopathological parameters of patients with type 1endometrial carcinoma such as tumor grade, lymhovascular invasion, age of pateints, tumor stage, presence of myometrial invasion and presence of cervical stroma affection.
  3. 3.To assess correlation of METTL-14 expression with disease free survival and overall survival.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
5mo left

Started Sep 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress60%
Sep 2025Oct 2026

First Submitted

Initial submission to the registry

February 22, 2025

Completed
12 days until next milestone

First Posted

Study publicly available on registry

March 6, 2025

Completed
7 months until next milestone

Study Start

First participant enrolled

September 27, 2025

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2026

Expected
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2026

Last Updated

September 30, 2025

Status Verified

September 1, 2025

Enrollment Period

10 months

First QC Date

February 22, 2025

Last Update Submit

September 29, 2025

Conditions

Endometrial CancerEndometrial Adenocarcinoma

Outcome Measures

Primary Outcomes (1)

  • Evaluation of immunohistochemical Expression of METTL14 in Type 1 Endometrial Carcinoma

    Measurement: Percentage of positive METTL14-stained tumor cells using immunohistochemistry (IHC). Unit: Percentage (%). Time Frame: Baseline.

    baseline

Study Arms (1)

endometrial carcinoma

Other: ObservationBehavioral: IHC

Interventions

ObservationOTHER

observation of METTL-14 prognosis

endometrial carcinoma
IHCBEHAVIORAL

IHC of METTL-14

endometrial carcinoma

Eligibility Criteria

Sexfemale
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

endometrial carcinoma

You may qualify if:

  • Cases of type1endometrial carcinoma with:
  • Hystrectomy operation
  • Available full clinical data about patient (age, complaint, findings in clinical examination).
  • Full data about previous biopsy and radiology.
  • Full data about patient survival, disease progression and history of chemotherapy for three years.

You may not qualify if:

  • \. Any case of type 1 endometrial carcinoma with missing clinical, radiologic or follow up data.
  • \. Cases with no available H\&E stained slides or formalin fixed paraffin embedded block.
  • D\&C.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

AssuitU

Asyut, Egypt

Location

MeSH Terms

Conditions

Endometrial Neoplasms

Interventions

Observation

Condition Hierarchy (Ancestors)

Uterine NeoplasmsGenital Neoplasms, FemaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Intervention Hierarchy (Ancestors)

MethodsInvestigative Techniques

Central Study Contacts

Monica Ashraf Alfy, Demonstrator

CONTACT

+2001550303582mony.ashraf@aun.edu.eg

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

February 22, 2025

First Posted

March 6, 2025

Study Start

September 27, 2025

Primary Completion (Estimated)

August 1, 2026

Study Completion (Estimated)

October 1, 2026

Last Updated

September 30, 2025

Record last verified: 2025-09

Locations

EG(1)